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From March 2003 to April 2004, 77 physicians throughout France prospectively recruited 1289 ductal carcinoma in situ (DCIS)
patients and collected data on diagnosis, patient and tumour characteristics, and treatments. Median age was 56 years (range, 30–84).
Ductal carcinoma in situ was diagnosed by mammography in 87.6% of patients. Mastectomy, conservative surgery alone (CS) and
CS with radiotherapy (CSþRT) were performed in 30.5, 7.8 and 61.7% of patients, respectively. Thus, 89% of patients treated by
CS received adjuvant RT. Sentinel node biopsy (SNB) and axillary dissection (AD) were performed in 21.3 and 10.4% of patients,
respectively. Hormone therapy was administered to 13.4% of the patients (80% tamoxifen). Median tumour size was 14.5mm
(6, 11 and 35mm for CS, CSþRT and mastectomy, respectively, Po0.0001). Nuclear grade was high in 21% of patients,
intermediate in 38.5% and low in 40.5%. Excision was considered complete in 92% (CS) and 88.3% (CSþRT) of patients. Oestrogen
receptors were positive in 69.8% of assessed cases (31%). Treatment modalities varied widely according to region: mastectomy rate,
20–37%; adjuvant RT, 84–96%; hormone treatment, 6–34%. Our survey on current DCIS management in France has highlighted
correlations between pathological features (tumour size, margin and grade) and treatment options, with several similar variations to
those observed in recent UK and US studies.
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In France, 49.236 new breast cancers were diagnosed in women in
2004 (Allemand et al, 2008). Between 2000 and 2004, the annual
incidence rate increased by 2%. However, the precise proportion
of ductal carcinoma in situ (DCIS) in France is unknown.
Presently, DCIS accounts for approximately 15–20% of all
breast cancers (Baxter et al, 2004; Leonard and Swain, 2004). The
French screening programme was introduced in several counties
(de ´partements) in 1989 and was progressively extended all over
France within the framework of the National Cancer Plan in 2000.
The national coverage was achieved in 2005. Ductal carcinoma
in situ rate among abnormal screen-detected mammographies
reached 13.8%. Ductal carcinoma in situ is treated by mastectomy
or conservative surgery (CS) with or without radiotherapy (RT)
(Morrow et al, 2002; Ceilley et al, 2004; Mokbel and Cutuli, 2006).
The best option is still a matter of debate, with wide differences in
practice observed across European countries and the United States
(Ceilley et al, 2004; Mokbel and Cutuli, 2006). Moreover, important
regional differences were also reported.
Up-to-date data on DCIS are not available for France. We
therefore performed a national prospective survey of the diagnosis,
histopathological features and treatment of pure DCIS in France
and compared our findings with those from other countries. The
methodology of this survey was similar to a study on invasive
breast cancer conducted in 2001–2002 (Cutuli et al, 2006).
MATERIALS AND METHODS
Our observational, prospective cross-sectional study was per-
formed from March 2003 to April 2004. A total of 77 physicians
took part in the study and were recruited in surgery, oncology and
radiation oncology departments throughout France. Most of them
participated in the first national survey on infiltrating breast
cancer in 2001–2002 (Cutuli et al, 2006). Those physicians are
coordinators of a local breast unit, or general or gynaecological
surgeons involved in breast cancer care. Finally, they are usually
good representatives of all French regions (urban and rural)
and types of sanitary structures. Indeed, patients were managed
in cancer centres (49% of patients), private clinics (33%), or
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suniversity or general hospitals (18%), reflecting quite well the daily
current practice in our country. All patients seen in each hospital
were prospectively included, but obviously with a more important
recruitment in several specialized centres (7 with more than
50 cases each).
Eligibility criteria were female gender, X18 years of age, with
a diagnosis of pure DCIS. Patients with microinvasive lesions,
previous or synchronous contralateral breast cancer or other
cancers were excluded.
We collected data on demographics (age, family history of breast
cancer, menopausal status, hormonal replacement therapy (HRT)),
clinical presentation, mammography findings, biopsy procedures,
specimen characteristics as given by the pathology report (tumour
subtype, size, grade, excision quality and hormone receptor status)
and treatment (types of surgery, number of operations, adjuvant
therapy (RT with or without boost and hormone therapy) (see
form in Supplementary Information). All data were checked
(exhaustive pathological forms, radiation doses and other treat-
ments) by the first author in collaboration with two pathologists of
the scientific committee (FP-L, EM) and the statistical team,
especially regarding some cases of ‘incoherencies’. The individual
survey forms were made by each physician who sent them to the
data management centre.
Statistical methods
We used SAS software (version 8.2, SAS Institute Inc., Cary, NC,
USA).
To compare two groups, we used the w
2 test for categorical
variables, the t-test for continuous variables and the non-
parametric Mann–Whitney test when the assumption of normality
was questionable. To compare more than two groups, we used the
w
2 test for categorical variables, one-way analysis of variance for
continuous variables and the non-parametric Kruskal–Wallis test
when the assumption of normality was questionable. Three
treatment groups were compared, namely CS alone (99 patients:
7.8%), CSþRT (797 patients: 61.7%) and mastectomy (393
patients: 30.5%). We also performed regional comparisons
dividing the country in five regions, namely Paris, northwest,
northeast, southeast and southwest. Finally, a multivariate analysis
was included, allowing predicting the therapeutic choices, such as
mastectomy vs CS as well as sentinel node biopsy (SNB) vs axillary
dissection (AD) according to age, tumour size (both quantitative
variables), or grade and the presence of necrosis (both qualitative
variables). A stepwise procedure was used to select variables for
the multiple logistic regression analysis.
RESULTS
Patient data
A total of 1289 patients were evaluable. Median age was 56 years
(range, 30–84). Age distribution was as follows: 4% below 40 years,
25% 40–49, 36% 50–59, 22% 60–69 and 13% over 70 years.
A family history of breast cancer was present in 30% of patients.
In total, 816 (63.3%) patients were menopausal (median age, 50
years); 52.3% of them had undergone HRT for a median duration
of 7.7 years.
Presentation at diagnosis
In 87.6% of patients, DCIS was diagnosed by mammographic
abnormality. Only 12% of patients had clinical symptoms, such as
palpable mass, Paget’s disease, serosanguineous nipple discharge
and/or retraction; such clinical symptoms were present in 9.5% of
CS groups (CS and CSþRT) compared with those in 17.3% of the
mastectomy group.
Mammography findings
Of 1235 abnormal mammograms, 1227 could be evaluated: 1012
(82.5%) showed microcalcifications only, 62 (5.6%) opacity, archi-
tectural distortion or increased density and 146 (11.9%) combinations
of these features. Of 1156 mammograms that could be evaluated
according to the Breast Imaging Reporting and Data System from
American College of Radiology (BI-RADS) classification, 107 (9.2%)
were BI-RADS 3, 720 (62.3%) BI-RADS 4 and 329 (28.5%) BI-RADS 5.
Preoperative biopsy
Preoperative needle biopsy was performed in 61.8% of patients.
Vacuum-assisted needle biopsy was performed in 66.4% of these
patients and stereotactic core-needle biopsy in 33.6%.
Histopathology
The tumour was excised as a single specimen in 94.4% of patients,
but one or more re-excisions proved necessary in 37% of patients.
Tumour size was evaluable in 1062 (82.4%) tumours: 431 (40.6%)
p10mm, 291 (27.4%) 11–20mm and 340 (32%) 420mm. Median
tumour size was 14.5mm: 6mm for CS, 11mm for CSþRT and
35mm for mastectomy (Po0.0001). Nuclear grade was low in 21%,
intermediate in 38.5% and high in 40.5% of tumours.
Excision was considered complete (usually margins X1mm) in
92% of CS patients and in 88.3% of CSþRT patients. The
corresponding percentages were 3 and 5.8% for doubtful excision,
4 and 2.4% for incomplete excision, with 1 and 3.5% for non-
evaluable excision. Tumour-free margins were measured in 66.7%
of CS patients and 70.3% of CSþRT patients. The margin was
o1mm in 10.6% (CS) and 12.1% (CSþRT) of patients, 1–3mm
in 21% of patients (whether CS or CSþRT), 4–10mm in 51.5%
(CS) and 57.1% (CSþRT) of patients, and 41cm in 16.7% (CS)
and 10.3% (CSþRT) of patients. Thus, we do not have any specific
analysis of multifocality and multicentricity, but we have the
notion of ‘residual tumour’ on the specimen in case of multiple
surgery, maximal tumour size and final margin status to predict
the best surgical option (especially mastectomy). Indeed, the
definitions of multifocality or multicentricity are often very
subjective and confusing, especially in case of several little foci
in the same area, but each one separated only by few millimetres.
Steroid hormone receptors were assayed in 31% of tumours.
Oestrogen receptors (ER) were positive in 70% of patients and
progesterone receptors in 59.5%. Hormonal replacement therapy had
no influence on lesion size, architectural subtype and hormone
receptor status, but was significantly associated with tumour grade.
Indeed, low-grade tumours were found in 26.2% of women who had
undergone HRT and in 18.3% who had not. Tumours were high
grade in 34.2% (HRT) and 47.6% (no HRT) of women (P¼0.0004).
Treatment
Out of 1289 patients, 896 (69.5%) underwent CS and 393 (30.5%)
mastectomy. The 69.5% undergoing CS could be further classified
into 7.8% who underwent just CS and 61.7% who received
adjuvant RT (89%). Generally, 70% of the patients underwent one
operation, 27% two and 3% three. Residual DCIS foci were found
in 59% of patients undergoing a second or third operation.
Mastectomy was performed in 40% of patients as a first option but
in 50% after one or two lumpectomies, and in 10% after
quadrantectomy. Most patients who underwent multiple opera-
tions ended up by having a mastectomy. The number of breast
surgical procedures was significantly reduced if a preoperative
biopsy (stereotactic core-needle biopsy and more specially
vacuum-assisted needle biopsy) was performed (Table 1). The
rate of AD was also significantly reduced by the preoperative
biopsy use, whereas the rate of SNB was increased (Table 2).
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sTumour size, nuclear grade, necrosis and age significantly
influenced treatment modalities (Table 3). Mastectomy was used
to treat 41% of high-grade tumours vs 15.3% of low-grade
tumours. Generally, 93% of the patients with tumours p10mm
were treated by CS (84.5% with RT) and 63.2% of patients with
tumours X20mm underwent mastectomy. Mastectomy rates were
43% for comedocarcinoma and 28% for other lesions (Po0.0001).
Conservative surgery was used to treat 1.5% of comedocarcinoma
and 9.5% of other lesion subtypes (Po0.0001). The multiple
logistic regression analysis confirmed that the factors significantly
influencing the mastectomy choice were tumour size (OR: 1.088),
young age (OR: 0.975) and high or intermediate grade (Table 4).
Of 896 women who were treated by CS, 797 (89%) received
adjuvant RT. The median dose administered to the whole breast
was 50Gy. A 10Gy boost (median dose) was given to 49% of
patients (48% if excision was complete and 63.1% in case of
incomplete or doubtful excision (P¼0.018).
Tumour size, nuclear grade, lesion subtype (comedo vs others)
and treatment strongly influenced axilla treatment (Table 5).
Generally, 21.3% of patients underwent SNB and 10.4% AD. The
multiple logistic regression analysis showed that sentinel biopsy
procedure rates were higher in case of mastectomy, comedocarci-
noma subtypes, large tumour size and high-grade lesions (Table 6).
The AD use was significantly and only correlated to the
mastectomy option (OR: 5.83; IC 95%: 3.68–9.24, Po0.001).
Adjuvant hormone therapy was administered to 172 (13.4%)
patients; 138 received tamoxifen (80%), 7 a luteinizing hormone-
releasing hormone (LH-RH) agonist and 25 an aromatase inhibitor.
Regional variations in practice
There are some variations among regions in histopathological
diagnosis (e.g., percentage of high-grade lesions, comedocarci-
noma subtype and ER assessment) as well as in treatments
(Table 7). The mastectomy rate ranged from 35 to 50% for high-
grade DCIS and from 38.5 to 50% for comedocarcinoma. It varied
from 20 to 37% according to the region. There were also wide
regional variations in the delivery of adjuvant RT (81–96%) and in
the administration of adjuvant hormone therapy (6–34%).
Mastectomy rates also varied according to the type of institution
(37.4, 32 and 19.4% in cancer centres, academic or general
hospitals and private clinics, respectively, Po0.0001). The
corresponding CSþRT rates were 87.3, 81.3 and 94.2%.
DISCUSSION
Our survey was conducted to obtain comprehensive and
unselected up-to-date data on diagnosis, assessment and treatment
of DCIS in France. The 77 physicians who included patients are
breast cancer specialists working in different types of institutions
(cancer centres, clinics and hospitals), reflecting the current daily
practice in our country. However, we may have a small
overrepresentation in our study of large centres.
Since 2000, regional breast cancer screening programmes in
France have targeted women aged from 50 to 74 years. Ductal
carcinoma in situ was diagnosed by mammography in 87.6% of
our patients, but only in 61.2% of patients under the age of 40
years. This 87.6% rate of mammographically detected DCIS is
slightly higher than the mean 81.5% rate of infraclinical lesions
found in a former review of 909 patients treated for DCIS in
Bordeaux) (Barreau et al, 2005). French (Cutuli et al, 2005a,b) and
European (Rutgers, 2001) guidelines also recommend preoperative
diagnosis. Our study confirmed that preoperative biopsy signifi-
cantly decreased the number of breast surgical procedures as well
as AD and should be performed routinely (Table 1).
Our mastectomy rate is identical to that reported by two recent
American and English studies (30.5%) (Katz et al, 2005; Dodwell
et al, 2007). In the United States, the overall mastectomy rate
decreased from 43% in 1992 to 37% in 1995 and 28% in 1999
(Ernster et al, 2000; Baxter et al, 2004; Mokbel and Cutuli, 2006).
However, this rate was much higher (58%) in a large series from
the Netherlands Cancer Institute (Meijnen et al, 2008). Tumour
Table 1 Correlation between number of extra surgical procedures and
pre-operative biopsy (percent patients)
Number of extra
surgical procedures No biopsy SCNB VANB
CS and CS+RT n¼257 n¼175 n¼334
1 72.4 83.4 92.3
2 or 3 27.6 16.6 7.7
Mastectomy n¼138 n¼91 n¼163
1 10.1 53.8 58.3
2 or 3 89.9 46.2 41.7
Abbreviations: CS¼conservative surgery; RT¼radiotherapy; SNCB¼stereotactic
core-needle biopsy; VANB¼vacuum-assisted needle biopsy. Po0.0001 for each
comparison between treatments according to w
2-test.
Table 2 Influence of pre-operative surgery on axilla surgery (% of patients)
No biopsy Previous biopsy P-value
Sentinel node biopsy 15.4 25 o0.0001
Axillary dissection 14 8.2 0.0009
Table 3 Influence of tumour size, nuclear grade, necrosis and age on
treatment modality (number and percent patients)
CS CS+RT Mastectomy Total
N % N % N % N %
Tumour size (pT, mm)
a
p10 62 14.4 339 78.6 30 7 431 40.6
11–20 14 4.8 223 76.6 54 18.6 291 27.4
420 5 1.5 120 35.3 215 63.2 340 32
Grade
b
Low 56 20.9 171 63.8 41 15.3 268 21
Intermediate 30 6.2 322 65.7 138 28.1 490 38.5
High 12 2.3 294 57.1 209 40.6 515 40.5
Necrosis
c
None necrosis 68 13.4 334 65.9 105 20.7 507 42
No comedo necrosis 15 6.6 136 59.6 77 33.8 228 19
Comedo necrosis 9 1.9 271 57.2 194 40.9 474 39
Age (years)
o50 26 26.2 203 25.5 141 35.9 370 28.7
50–60 41 41.4 284 35.6 136 34.6 461 35.8
61–70 14 14.1 198 24.8 73 18.6 285 22.1
470 18 18.2 112 14.1 43 10.9 173 13.4
Abbreviations: CS¼conservative surgery; RT¼radiotherapy. Evaluable cases:
a1062
(82.4%);
b1273 (98.7%); and
c1209 (93.8%).
Table 4 Mastectomy option influencing factors: multiple logistic
regression analysis by stepwise procedure
Variable WALD value v
2 P-value OR IC 95%
Tumour size (mm) 187 o0.0001 1.088 1.075–1.1
Age (years) 9.09 0.0026 0.975 0.96–0.99
Low grade 6.94 0.0084 0.497 0.29–0.83
Abbreviation: OR¼odds ratio.
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ssize, grade and necrosis are important factors in the decision to
perform mastectomy. In our series, mastectomy was performed in
10% of patients with DCIS o10mm but in 72% of patients with
DCIS 420mm, in 11% of patients with low-grade DCIS but in 54%
with high-grade DCIS. On the other hand, several recent papers
have emphasised the high risk of local recurrence (LR) in young
women after CS, with or without RT in both retrospective studies
and randomized trials (Fisher et al, 2001; Solin et al, 2001; Cutuli
et al, 2002; Fourquet et al, 2002; Vicini and Recht, 2002; Bijker
et al, 2006). These data probably explain our 50% mastectomy
rates in women under the age of 40 years.
In theory, there is no axillary lymph node involvement in DCIS,
although a recent review has reported 1.4% involvement in 1621
patients with pure DCIS (Morrow et al, 2002; Leonard and Swain,
2004). There may, however, be a risk of associated microinvasive foci,
especially when the lesion is extensive (McMasters et al, 2002; Moran
et al, 2005; Tunon de Lara et al, 2008). This may be a reason why,
even though axilla management is pointless, 10.4% of our patients
underwent AD and 21.3% underwent SNB. The potential risk of
axillary lymph node involvement was probably overestimated by
several physicians. The AD practice was highly influenced by tumour
size and nuclear grade (Table 5), but especially by the breast surgery
type; indeed, the AD rate was 5% after CS vs 22.6% after mastectomy
(Po0.001). The global AD rate recorded in an earlier study by French
Cancer Centres, including 1223 patients treated from 1985 to 1996 was
51.3% (Cutuli et al, 2005a,b). Such a steep decrease (from 51.3 to
10.4% in France) has already been observed in the United States,
where the global AD rate decreased from 34% in 1992 to 15% in 1999
(Po0.001), but nevertheless still remained high (30%) in 1999 in
mastectomy patients (Baxter et al, 2004). In another US study (Smith
et al, 2006), AD rate ranged from 18 to 28% across different sites. At
present, AD is useless and should be replaced by SNB. In our study,
SNB rate was 12.3% after CS vs 41.7% after mastectomy (Po0.001).
Finally, a recent French multicentric study (Tunon de Lara et al, 2008)
including 116 large DCIS found 4 positive sentinel nodes (3.4%).
Thus, SNB could be proposed in patients treated by mastectomy.
For most authors, complete tumour excision is the key factor in
reducing LR after CS (Silverstein et al, 1999; Kell and Morrow,
2005; MacDonald et al, 2005), but can be difficult to achieve.
However, there is no clear consensus on the definition of
‘complete’ excision and adequate margins (Schwartz et al, 2000;
Kell and Morrow, 2005). Tumour size and excision quality are
factors often omitted in the reports of randomized controlled trials
(Bijker et al, 2001) and retrospective studies (Solin et al, 2001). In
our recent national practice guidelines (Cutuli et al, 2005a,b), we
have defined complete excision as a resection with at least 3mm
circumferential margins. Approximately 76% of our patients
underwent complete tumour excision according to this criterion.
However, some teams consider a 2mm margin to be adequate if
the patient subsequently receives RT (Kell and Morrow, 2005).
In patients with tumour excision who did not receive RT, the
10-year LR rates ranged from 19 to 27.8% (Schwartz, 2002). In four
randomized controlled trials, the LR rates after CS without RT were 32,
28, 26 and 22%, with follow-ups ranging from 52 to 120 months (Fisher
et al, 2001; Hougton et al, 2003; Bijker et al, 2006; Holmberg et al,
2008). In a French study, the 7-year LR rate was 32.4% in patients not
receiving RT (Cutuli et al, 2002). In two latest Dutch studies (Schouten
Van Der Velden et al, 2007; Meijnen et al, 2008), the 8- and 10-year LR
Table 5 SNB and AD practice according to age, treatment and tumour
characteristics
N SNB % AD % P-value
Tumour size (cm)
(1)
o10 431 11.1 5.6
10–20 291 18.2 10.3 o0.0001
420 340 36.3 17.3
Nuclear grade
(2)
Low 268 11.2 5.2
Intermediate 490 18.2 10.4 0.0025
High 515 29.7 13.2
Lesion subtype
(3)
Comedo 272 31.6
a 11.4
b o0.0001
a
Other 851 18.1 10.3 0.6
b
Treatment
CS 99 7.1 4
CS+RT 797 12.9 5.1 o0.0001
Mastectomy 393 41.7 22.6
Age (years)
o50 370 26.8
c 10.3
d
50–60 461 20.4 10.2 0.0074
c
61–70 285 15.8 11.2 0.5
d
470 173 20.8 9.8
Abbreviations: AD¼axillary dissection; CS¼conservative surgery; RT¼radiotherapy;
SNB¼sentinel node biopsy. Missing values:
(1) 227;
(2) 16;
(3) 166.
aP-value between
lesion subtype (comedo versus other) for SNB.
bP-value between lesion subtype
(comedo versus other) for AD.
cP-value according to age (o50 vs 450years) for
SNB.
dP-value according to age (o50 vs 450years) for AD.
Table 6 Sentinel node biopsy influencing factors: multiple logistic
regression analysis by stepwise procedure
Variable WALD value v
2 P-value OR IC 95%
Mastectomy 30.58 o0.001 3.127 2.088–4.68
Comedocarcinoma 6.92 0.0085 1.64 1.13–2.38
Tumour size (mm) 9.57 0.002 1.014 1.005–1.023
Low grade 7.58 0.0059 0.438 0.243–0.788
Abbreviation: OR¼odds ratio.
Table 7 Regional variations in histopathological features and treatment modalities (% patients)
Paris Northwest Northeast Southwest Southeast
% of high-grade lesions 33 43 44 49 40
% of comedocarcinoma subtype 10 20 26 43 27
% ER assessment 14 12 60 53 31
CS 3 3 8 13 4
Median size (mm)
a 8 2.5 5 4 7
CS+RT 77 60 57 61 63
Mastectomy 20 37 35 26 33
Median size (mm)
b 40 30 42 27 40
IR 39 64 37 66 64
Hormone therapy 13 6 34 9 12
Abbreviations: CS¼conservative surgery; ES¼oestrogen receptor; IR¼immediate reconstruction; RT¼radiotherapy.
aIn patients treated by CS alone.
bIn patients treated by
mastectomy.
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safter CS alone were 15.6 and 25%, respectively. Whole breast irradiation
at 50Gy after CS for DCIS halved in situ and invasive recurrence rates
in earlier quoted trials (Fisher et al, 2001; Hougton et al, 2003; Bijker
et al, 2006; Emdin et al, 2006; Holmberg et al, 2008) and several large
retrospective studies (Solin et al, 2001; Cutuli et al, 2002; Fourquet et al,
2002; Schouten Van Der Velden et al, 2007; Meijnen et al, 2008). On the
other hand, RT administration after wide excision (margins 41cm)of
small low-grade lesions is questioned (Cornfield et al, 2004;
MacDonald et al, 2005; Solin et al, 2006; Buchholz et al, 2007,
Silverstein et al, 2007). However, this result should be weighed up
against the 12% rate observed at 5 years in a series of low-risk patients
(Wong et al, 2006). On the other hand, the Van Nuys Prognostic Index
(VNPI), combining tumour size, grade and margin width, was used to
select ‘low-risk’ patients not requiring RT (Silverstein et al, 1996), but
was widely criticised in two large American and English studies
including 222 and 237 patients, respectively (Boland et al, 2003;
MacAusland et al, 2007). A recent Italian study (Di Saverio et al, 2008)
including 259 patients also used VNPI and concluded in the absence of
statistically significant advantage in the CSþRT vs the CS group.
However, the CSþRT group had several unfavourable factors widely
increasing LR risk, such as lesion size 415mm (67 vs 30%) and
excision margins o1mm(29vs 4%). These features clearly explain the
similarity of LR rates with an ‘apparent’ inefficiency of RT (7.5% for CS
and 9.5% for CSþRT). Despite this, other English studies still use
VNPI in current practice (Gilleard et al, 2008). Our survey showed that
89% of patients receive adjuvant RT after CS. A recent study on 1140
screen-detected DCIS in the United Kingdom reported a 57% ‘planned
RT’ after CS. The RT use was influenced by tumour size (less or more
than 15mm), the presence of comedonecrosis and, more particularly,
nuclear grade, but paradoxically not by margins (Dodwell et al, 2007).
Such differences may show the high confidence of France (and of many
centres in the United States and partly the United Kingdom) in
randomised trials and large unselected retrospective studies on RT after
CS for pure DCIS. Besides, there is clear evidence that boost increases
local control in invasive breast cancer, especially in women under the
a g eo f5 0y e a r s( B a r t e l i n ket al, 2001). A boost was given to 49% of our
RT patients compared with 50–75% of patients in other studies (Cutuli
et al, 2002; Fourquet et al, 2002; Solin et al, 2005). A recent study
(Omlin et al, 2006) on 375 young women (p45 years) treated for pure
DCIS showed 28 and 14% LR rates with and without a 10Gy boost.
This 50% LR reduction rate is identical to that in invasive BC. However,
there are several limitations in this study, that is long recruitment
period, lack of specification on margin status and types of surgery.
The NSABP-24 trial (Fisher et al, 1999, 2001) found a significant
reduction in ipsilateral and contralateral tumours on combining
tamoxifen with CSþRT, which was however not confirmed by the
results of a randomized trial from the United Kingdom, Australia and
New Zealand (Hougton et al, 2003). Tamoxifen was effective in
patients with ER-positive tumours only (37% of the patients in the
NSABP trial) but not in patients with negative margins, absence of
necrosis and in women over 50 years (Allred et al, 2002; Fisher et al,
2002). It has some serious side effects (endometrial cancer and
thromboembolic events) and various ‘minor’ others. In a study of 94
patients with DCIS, 20 (21%) discontinued tamoxifen because of side
effects or complications (mainly hot flushes, fatigue, weight gain and
gynaecological or digestive symptoms) (Yen et al, 2004). The tumours
of 31% of our patients were assayed for ER and progesterone
receptors. The positivity rate was 70% for ER and 60% for
progesterone receptors, in line with the 64 and 57% rates,
respectively, recorded in a review of 1920 patients (Baxter et al, 2004).
There were important regional differences in histopathological
features as well as treatment in our study population (Table 7). The
mastectomy rate ranged from 20 to 37% and the use of RT after CS
from 82 to 96%. Tamoxifen use varied widely from 6% in the
northwest to 34% in the northeast of France. On the other hand, the
size of DCIS ‘selected’ for CS alone ranged from 2.5 to 8mm. It is also
important to point out that wide histopathological variations (partly
unexplained) can induce various therapeutic procedures.
Physician discretion and habitual practice rather than actual
differences in DCIS probably explain these variations. Indeed, in the
above-mentioned UK study (Dodwell et al, 2007), among 69 breast
screening units included in the study, wide variations in the use of
adjuvant RT were observed, ranging from 0% in six units to 100% in
two (median: 57.7%). The authors explain that such variations in the
use of RT reflect the differences in the perception of the risk–benefit
relationship in this treatment, and also probably some difficulties to
have access to RT facilities (Dodwell and Crellin, 2006). Wide
variations have also been recorded in the United States (Ceilley et al,
2004; Katz et al, 2005), especially in the mastectomy rates (range: 26–
45%) and the use of RT after CS (range: 39–74%), and have been
confirmed in a recent analysis of the SEER data (Smith et al, 2006). In
a retrospective study on 727 patients with DCIS enrolled in the
Ontario Breast Screening Program from 1991 to 2000 (Rakovitch et al,
2007), there were also significant regional variations in RT use after
BCS, ranging from 43 to 71% regardless of tumour pathological
features, surgeon and hospital volume. On the other hand, some
physicians are afraid by possible RT side effects. However, with
modern techniques, the ‘simple’ whole breast irradiation (with or
without boost, but without nodal irradiation) delivering 50Gy in 25
fractions (or equivalent dose) resulted in o1% of complications,
whereas in case of invasive LR, 15–20% of the patients finally died by
metastatic evolution (Mokbel and Cutuli, 2006; Silverstein et al, 1998).
Moreover, in the study reporting the SEER results (Warren et al,
2005), LR rates after CS and CSþRT were 15 and 10.7%, respectively,
with a significant increase in breast cancer-related deaths when RT
was omitted: 2.7 vs 0.8% (P¼0.02).
In conclusion, randomised controlled trials can provide some
answers, even if they are not exempt from criticism (Bijker et al,
2002). Several selection biases have been noted in DCIS trials such
as inclusion of benign or microinvasive lesions and lack of
compliance with study criteria (lesion size/surgical margins,
quality of excision and treatment modalities) (Mokbel and Cutuli,
2006). However, there are now very consistent data confirming the
importance of RT to minimise LR risk rates after CS for most
DCIS, such as shown in a large study including 23547 women from
the California Cancer Registry (Innos and Horn-Ross, 2008). The
future trials should identify more clearly selected patients (i.e.,
older than 60 years, with low-grade lesions under 10mm and clear
margin over 10mm), in which RT can be safely omitted, and also
those with aggressive DCIS requiring mastectomy.
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